Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This study suggests that scalp rolling could be a promising and affordable adjuvant treatment for alopecia areata, potentially promoting hair regrowth by enhancing the effects of topical medications and inducing collagen.

This case report found that a patient with ritlecitinib-resistant alopecia areata experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential effectiveness and suggesting benefits of personalized treatment strategies targeting the JAK1-mediated pathway.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

In this case report, researchers describe a 44-year-old woman with refractory patch alopecia areata achieving complete hair regrowth using a multi-modal approach of systemic and topical cholecalciferol with microneedling, although systemic vitamin D repletion remains a significant confounder.

This study found that phototherapy was more effective for patients with the multiple or totalis types of alopecia areata, with whole-body phototherapy potentially benefiting those with refractory universalis type.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, predominantly pitting, which was significantly linked to longer disease duration but not the severity of scalp hair loss.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, and while this was associated with longer disease duration, it did not correlate with the severity of scalp hair loss.

This review discusses the unclear etiology and potential contributing factors of frontal fibrosing alopecia and reports no new clinical findings.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

This study found that individualized homeopathic medicine can significantly improve outcomes in patients with alopecia areata, including complete hair regrowth and reduced SALT scores within 5 to 12 months, without relapse, and shows promise for alopecia universalis through targeted miasmatic and constitutional remedies.

In this study, two female patients with severe, treatment-resistant alopecia areata showed significant hair regrowth after a single session of intradermal administration of adipose tissue–derived exosomes, without experiencing adverse events, suggesting a promising therapeutic strategy for refractory cases.

This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

This meta-analysis found that traditional Chinese medicine may be an effective and safe adjuvant therapy for androgenetic alopecia, improving efficacy rates and symptom scores compared to conventional medicine.

The reported treatment depths were likely incorrect and could risk patient safety.

Combining PRP, microneedling, and minoxidil may improve hair regrowth in severe hair loss cases.

In this study, researchers evaluated the use of adipocyte-derived stem cell conditioned media combined with fractional laser or microneedling for treating refractory alopecia areata, finding that 64.3% of patients had significant hair regrowth, suggesting this combination may be an effective and safe treatment option.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This study presents two cases where intralesional methotrexate combined with ablative fractional CO2 laser treatment resulted in excellent outcomes for refractory alopecia areata.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.

Combining PRP with microneedling and minoxidil may help treat severe hair loss.

This article discusses temporal triangular alopecia, emphasizing the need for increased awareness to prevent misdiagnosis and ineffective treatment, but reports no new clinical results.